Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

S. Borstnar, M. Palacova, A. Łacko, C. Timcheva, EN. Gal-Yam, K. Papazisis, J. Beniak, P. Kudela, G. Rubovszky

. 2022 ; 56 (2) : 238-247. [pub] 20220517

Jazyk angličtina Země Polsko

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018394

BACKGROUND: The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients with HR+/HER2- ABC (MONALEESA-7). The multinational, phase 3b, CompLEEment-1 trial, which assessed the safety and efficacy of ribociclib plus letrozole in a broader population of patients who have not received prior endocrine therapy for advanced disease, is the largest phase 3 clinical trial to date to evaluate the safety and efficacy of a CDK4/6 inhibitor. We report a subanalysis of data from patients (N = 339) enrolled in the central and south European countries of the SERCE (Southern Europe, RUC, Central Europe) cluster of CompLEEment-1. PATIENTS AND METHODS: Men and women of any menopausal status with HR+/HER2- ABC received once-daily oral ribociclib 600 mg (3-weeks on/1-week-off), plus letrozole 2.5 mg continuously. Men/premenopausal women also received a GnRH-agonist. The primary outcome was the number of patients with adverse events (AEs) over a timeframe of approximately 36 months. Time-to-progression, overall response rate, and clinical benefit rate were also measured. RESULTS: Safety results in the SERCE subgroup were consistent with those in the pivotal clinical trials of ribociclib in combination with endocrine therapy. Treatment-related AEs leading to dose adjustments/interruption occurred in 63.1% of patients but led to treatment discontinuation in only 10.6%. The most common treatment-related AEs of grade ≥ 3 were neutropenia and transaminase elevations. There were no fatal treatment-related events. CONCLUSIONS: These findings from the SERCE subgroup support the safety and manageable tolerability of ribociclib in a broad range of patients with HR+/HER2- ABC more representative of patients in real-world clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018394
003      
CZ-PrNML
005      
20220804134739.0
007      
ta
008      
220720s2022 pl f 000 0|eng||
009      
AR
024    7_
$a 10.2478/raon-2022-0020 $2 doi
035    __
$a (PubMed)35575587
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Borstnar, Simona $u Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
245    10
$a Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial / $c S. Borstnar, M. Palacova, A. Łacko, C. Timcheva, EN. Gal-Yam, K. Papazisis, J. Beniak, P. Kudela, G. Rubovszky
520    9_
$a BACKGROUND: The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients with HR+/HER2- ABC (MONALEESA-7). The multinational, phase 3b, CompLEEment-1 trial, which assessed the safety and efficacy of ribociclib plus letrozole in a broader population of patients who have not received prior endocrine therapy for advanced disease, is the largest phase 3 clinical trial to date to evaluate the safety and efficacy of a CDK4/6 inhibitor. We report a subanalysis of data from patients (N = 339) enrolled in the central and south European countries of the SERCE (Southern Europe, RUC, Central Europe) cluster of CompLEEment-1. PATIENTS AND METHODS: Men and women of any menopausal status with HR+/HER2- ABC received once-daily oral ribociclib 600 mg (3-weeks on/1-week-off), plus letrozole 2.5 mg continuously. Men/premenopausal women also received a GnRH-agonist. The primary outcome was the number of patients with adverse events (AEs) over a timeframe of approximately 36 months. Time-to-progression, overall response rate, and clinical benefit rate were also measured. RESULTS: Safety results in the SERCE subgroup were consistent with those in the pivotal clinical trials of ribociclib in combination with endocrine therapy. Treatment-related AEs leading to dose adjustments/interruption occurred in 63.1% of patients but led to treatment discontinuation in only 10.6%. The most common treatment-related AEs of grade ≥ 3 were neutropenia and transaminase elevations. There were no fatal treatment-related events. CONCLUSIONS: These findings from the SERCE subgroup support the safety and manageable tolerability of ribociclib in a broad range of patients with HR+/HER2- ABC more representative of patients in real-world clinical practice.
650    _2
$a aminopyridiny $7 D000631
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a nádory prsu $x farmakoterapie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a letrozol $x terapeutické užití $7 D000077289
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a puriny $7 D011687
650    _2
$a receptor erbB-2 $x terapeutické užití $7 D018719
650    _2
$a receptory pro estrogeny $x terapeutické užití $7 D011960
650    _2
$a receptory progesteronu $x terapeutické užití $7 D011980
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Palacova, Marketa $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Łacko, Aleksandra $u Department of Clinical Oncology, Wroclaw University of Medicine, Wrocław, Poland, and Breast Unit, Lower Silesian Oncology Centre, Wroclaw, Poland
700    1_
$a Timcheva, Constanta $u Medical Oncology Clinic, Multiprofile Hospital for Active Treatment "Nadezhda" Sofia, Sofia, Bulgaria
700    1_
$a Gal-Yam, Einav Nili $u Talpiot medical leadership program, Institute of Oncology, Chaim Sheba Medical Center, Tel-Hashomer; affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
700    1_
$a Papazisis, Konstantinos $u Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece
700    1_
$a Beniak, Juraj $u Regional Cancer Center, Poprad, Slovakia
700    1_
$a Kudela, Pavol $u Novartis Slovakia s.r.o., Bratislava, Slovakia
700    1_
$a Rubovszky, Gábor $u Department of Oncological Internal Medicine and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
773    0_
$w MED00004048 $t Radiology and oncology $x 1581-3207 $g Roč. 56, č. 2 (2022), s. 238-247
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35575587 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134733 $b ABA008
999    __
$a ok $b bmc $g 1822135 $s 1169637
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 56 $c 2 $d 238-247 $e 20220517 $i 1581-3207 $m Radiology and oncology $n Radiol. oncol. (Tik. izd.) $x MED00004048
LZP    __
$a Pubmed-20220720
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace